Adaptive metabolic pattern biomarker for disease monitoring and staging of lung cancer with liquid biopsy.
Manuel Garcia-AlgarAna Fernandez-CarrascalAna Olano-DazaLuca GuerriniNeus FeliuWolfgang J ParakRoger GuimeràEduardo Garcia-RicoRamon A Alvarez-PueblaPublished in: NPJ precision oncology (2018)
In this manuscript, we demonstrate the applicability of a metabolic liquid biopsy for the monitoring and staging of patients with lung cancer. This method provides an unbiased detection strategy to establish a more precise correlation between CTC quantification and the actual burden of disease, therefore improving the accuracy of staging based on current imaging techniques. Also, by applying statistical analysis techniques and probabilistic models to the metabolic status and distribution of peripheral blood mononuclear cell (PBMC) populations "perturbed" by the presence of CTCs, a new category of adaptive metabolic pattern biomarker (AMPB) is described and unambiguously correlated to the different clinical stages of the patients. In fact, this strategy allows for classification of different categories of disease within a single stage (stage IV) before computed tomography (CT) and positron emission tomography (PET) scans and with lower uncertainty.
Keyphrases
- computed tomography
- positron emission tomography
- pet ct
- peripheral blood
- lymph node
- dual energy
- contrast enhanced
- magnetic resonance imaging
- pet imaging
- end stage renal disease
- high resolution
- image quality
- newly diagnosed
- prognostic factors
- ejection fraction
- machine learning
- deep learning
- single cell
- ionic liquid
- ultrasound guided
- peritoneal dialysis
- chronic kidney disease
- magnetic resonance
- label free